1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Investment is additive to KKR’s existing health care growth strategy
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
